drug
as of 2026-07-01Raloxifene
raloxifene
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Fundació Sant Joan de Déu
5 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
5
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder
NCT03043820Phase 3Completed
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women
NCT01573637Phase 3Completed
Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder
NCT01280305Phase 3Unknown
Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women
NCT01041092Phase 4Completed
The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study
NCT00206557Phase 2Completed
KOLs & investigators
8
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication
indication
indication
KOL
Iris E.C. Sommer, Prof. Dr.
personKOL score 16
Mark Weiser, MD
personKOL score 9
Janna de Boer, MD
personKOL score 6
Jayashri Kulkarni, MBBS, MPM, FRANZCP, PHD
personKOL score 5